259 related articles for article (PubMed ID: 26700708)
1. Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.
Deek MP; Benenati B; Kim S; Chen T; Ahmed I; Zou W; Aisner J; Jabbour SK
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):147-154. PubMed ID: 26700708
[TBL] [Abstract][Full Text] [Related]
2. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric predictors of acute haematological toxicity in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy.
Lee J; Lin JB; Sun FJ; Lu KW; Lee CH; Chen YJ; Huang WC; Liu HC; Wu MH
Br J Radiol; 2016 Oct; 89(1066):20160350. PubMed ID: 27556422
[TBL] [Abstract][Full Text] [Related]
4. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Tang C; Lee MS; Gomez D; Levy LB; Zhuang Y; Lu C; Liao Z; Komaki R
Am J Clin Oncol; 2017 Dec; 40(6):625-630. PubMed ID: 26165417
[TBL] [Abstract][Full Text] [Related]
5. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Lee AY; Golden DW; Bazan JG; Kopec M; Pelizzari CA; Aggarwal S; Chang DT; Liauw SL
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):306-312. PubMed ID: 28068238
[TBL] [Abstract][Full Text] [Related]
6. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.
Jiang N; Chen XC; Zhao Y
Support Care Cancer; 2013 Mar; 21(3):785-91. PubMed ID: 22936496
[TBL] [Abstract][Full Text] [Related]
8. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
[TBL] [Abstract][Full Text] [Related]
9. Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity.
Zhang A; Deek MP; Kim S; Sayan M; Grann A; Wagman RT; Malhotra U; Hathout L; Biswal N; Zhang Y; Langenfeld J; Kennedy T; August DA; Jabbour SK
J Gastrointest Oncol; 2019 Jun; 10(3):513-522. PubMed ID: 31183202
[TBL] [Abstract][Full Text] [Related]
10. [Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].
Wang J; Pang QS; Wang P; Wang J; Wang W
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):769-72. PubMed ID: 18396691
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy.
Newman NB; Sidhu MK; Baby R; Moss RA; Nissenblatt MJ; Chen T; Lu SE; Jabbour SK
Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1052-60. PubMed ID: 27026312
[TBL] [Abstract][Full Text] [Related]
12. Association of oesophageal radiation dose volume metrics, neutropenia and acute radiation oesophagitis in patients receiving chemoradiotherapy for non-small cell lung cancer.
Everitt S; Duffy M; Bressel M; McInnes B; Russell C; Sevitt T; Ball D
Radiat Oncol; 2016 Feb; 11():20. PubMed ID: 26864559
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
[TBL] [Abstract][Full Text] [Related]
14. Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer.
Niho S; Kubota K; Nihei K; Sekine I; Sumi M; Sekiguchi R; Funai J; Enatsu S; Ohe Y; Tamura T
Clin Lung Cancer; 2013 Jan; 14(1):62-9. PubMed ID: 22633219
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
[TBL] [Abstract][Full Text] [Related]
16. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
Pöttgen C; Eberhardt WE; Gauler T; Krbek T; Berkovic K; Jawad JA; Korfee S; Teschler H; Stamatis G; Stuschke M
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):809-15. PubMed ID: 19427744
[TBL] [Abstract][Full Text] [Related]
17. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
[TBL] [Abstract][Full Text] [Related]
18. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
[TBL] [Abstract][Full Text] [Related]
19. Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation.
Rose B; Mitra D; Hong TS; Jee KW; Niemierko A; Drapek LN; Blaszkowsky LS; Allen JN; Murphy JE; Clark JW; Ryan DP; Wo JY
Pract Radiat Oncol; 2017; 7(5):e291-e297. PubMed ID: 28462895
[TBL] [Abstract][Full Text] [Related]
20. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
Wan J; Liu K; Li K; Li G; Zhang Z
Radiat Oncol; 2015 Aug; 10():162. PubMed ID: 26238572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
